ESPR - NASDAQ
Esperion Therapeutics, Inc.
$3.14
+0.32%Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
At a Glance
Live SnapshotEsperion Therapeutics, Inc. Management Team
Tiffany Aldrich M.B.A.
Associate Director of Corporate Communications
Ms. Betty Jean Swartz
Chief Business Officer
Mr. Benjamin Halladay M.B.A.
Chief Financial Officer
Compensation
$713,958
Mr. Glenn P. Brame
Chief Technical Operations Officer
Mr. Benjamin O. Looker J.D.
General Counsel & Corporate Secretary
Compensation
$696,350
Mr. Sheldon L. Koenig
President, Chief Executive Officer & Director
Compensation
$1,262,378
Dr. Stephen Pinkosky
Vice President of Drug Discovery of Early Pre-Clinical Development
Esperion Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $40K and sold $453K worth of ESPR shares, resulting in $413K of net selling activity.
3 Months
0
0.00
37.7K
102.35K
-102K
-$102K
3-6 Months
0
0.00
63.8K
232.87K
-233K
-$233K
6-9 Months
0
0.00
41.7K
116.61K
-117K
-$117K
9-12 Months
40.0K
40.00K
1.3K
1.48K
+39K
+$39K
Top Buyers
Thompson John Craig
Director
$40K
Top Sellers
Koenig Sheldon L.
Director, Officer: President And Ceo
$326K
Halladay Benjamin
Officer: Chief Financial Officer
$64K
Looker Benjamin
Officer: Chief Legal Officer
$63K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $413K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ESPR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 17, 2025 | April 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 11, 2024 | April 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 13, 2023 | April 13, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | August 18, 2022 | September 20, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | April 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 15, 2021 | May 27, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 16, 2020 | May 28, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 18, 2019 | May 29, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 13, 2018 | May 23, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.